Cancer therapy-related cardiac dysfunction (CTRCD) is a well-known complication in breast cancer patients exposed to anthracyclines and Human Epidermal Growth Factor Receptor 2 (HER2) targeted therapy. However, the incidence of CTRCD in unselected contemporary breast cancer populations treated according to curren...
V. Vinje, E. Orstad, G. Gulati et al.· European Heart Journal· 0 citations
The CARE study is a large prospective observational cardio-oncology study evaluating the incidence of CTRCD after contemporary breast cancer therapy regimens and the performance of the HFA-ICOS risk stratification tool and follow-up strategies in routine cardio-oncology care.
V. Vinje, E. Orstad, G. Gulati et al.· European Heart Journal, Supp...· 0 citations
Baseline biomarker levels were not associated with GLS deterioration, and no biomarker–treatment interactions were observed (all p for interaction >0.27).Early post-anthracycline changes in hs-cTnI, hs-cTnT, or NT-proBNP were not predictive of subsequent GLS decline, nor were peak or persistent elevations (Table 1, Fig...
M. Gynnild, G. Gulati, A. Mecinaj-Lilleaasen et al.· European Heart Journal, Supp...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.